• Hormone replacement therapy for oestrogen deficiency symptoms in postmenopausal women more than 1 year postmenopause. • Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis. (See also Section 4.4)
FDA has accepted for review the resubmitted new drug application for the transdermal sumatriptan migraine patch NP101 fom NuPathe. The...
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., has announced the FDA approved Secuado (asenapine) transdermal system,...
Alvogen has launched the first generic equivalent of Exelon patch (rivastigmine transdermal system) in the United States. The product will...
The FDA is investigating the risk of serious burns and potential permanent scarring with the use of Zecuity (sumatriptan iontophoretic...
Studies of IQP-0410, from ImQuest Biosciences, a promising HIV therapeutic, demonstrate that it can be applied to the skin of...
ProStrakan, a subsidiary of Kyowa Hakko Kirin, has received EC approval for Sancuso (granisteron transdermal patch0 in Europe. Sancuso is...